Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.
Synklino has raised €30M across 2 funding rounds from 2 investors, most recently a Series A round in Jun 2022. Based in Lyngby, Denmark; founded 2017; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-06-09 | Series A | €30M | — | View deal → |
| 2020-10-07 | Other | €0 | EIR Ventures,Vaekstfonden | View deal → |
